{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:18:30Z","timestamp":1790741910101,"version":"4.1.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:00:00Z","timestamp":1788739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:00:00Z","timestamp":1788739200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastrointest Canc"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Lateral pelvic lymph node (LPLN) involvement is a significant predictor of local recurrence in patients with locally advanced rectal cancer (LARC). While lateral pelvic lymph node dissection (LPLND) is routinely used in some countries to manage suspicious nodes, it is associated with increased morbidity and is not widely adopted in Western practice. Radiation boost (dose escalation) to involved LPLNs during neoadjuvant chemoradiotherapy (nCRT) has emerged as a potential non-surgical alternative. Despite increasing adoption of radiation boost to clinically involved LPLNs, there remains limited evidence defining its safety, oncologic benefit, and role relative to LPLND.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic search of MEDLINE, EMBASE, ClinicalTrials.gov, and Cochrane databases was conducted following PRISMA guidelines. Studies were included if they reported outcomes of radiation dose escalation specifically targeting radiologically suspicious LPLNs in the context of nCRT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Ten retrospective cohort studies encompassing 482 radiation boosted patients were included. Boost doses ranged from 35.0 to 60.2\u00a0Gy. Rates of Grade 2\u20133 toxicity ranged from 28.0% to 39.3% across individual studies, with only one study reporting a single Grade 4 adverse event. Across individual studies, reported nodal response rates ranged from 62.3% to 100%. Comparative studies suggest that radiation boost may improve local control and reduce LPLN recurrence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Current retrospective evidence suggests that radiation dose escalation to involved LPLNs is a promising treatment strategy; however, the available data are limited by retrospective study designs and substantial clinical heterogeneity. Given the absence of prospective evidence and lack of consensus in current guidelines, an important evidence gap remains. Well-designed prospective trials are warranted to define the role of LPLN boost relative to LPLND.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s12029-026-01580-1","type":"journal-article","created":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T09:10:11Z","timestamp":1788772211000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Evidence Gap in Managing Lateral Pelvic Lymph Nodes in Rectal Cancer: a Systematic Review of Radiation Boost Strategies"],"prefix":"10.1007","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-9119-9080","authenticated-orcid":false,"given":"Sedat Alp","family":"Pinar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tin-Ning","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia Yew","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,7]]},"reference":[{"issue":"3","key":"1580_CR1","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1245\/s10434-007-9696-x","volume":"15","author":"TH Kim","year":"2008","unstructured":"Kim TH, et al. Lateral lymph node metastasis is a major cause of locoregional recurrence in rectal cancer treated with preoperative chemoradiotherapy and curative resection. Ann Surg Oncol. 2008;15(3):729\u201337.","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"1580_CR2","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1200\/JCO.18.00032","volume":"37","author":"A Ogura","year":"2019","unstructured":"Ogura A, et al. Neoadjuvant (Chemo)radiotherapy With Total Mesorectal Excision Only Is Not Sufficient to Prevent Lateral Local Recurrence in Enlarged Nodes: Results of the Multicenter Lateral Node Study of Patients With Low cT3\/4 Rectal Cancer. J Clin Oncol. 2019;37(1):33\u201343.","journal-title":"J Clin Oncol"},{"issue":"6","key":"1580_CR3","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1002\/ags3.12490","volume":"5","author":"TC Sluckin","year":"2021","unstructured":"Sluckin TC, Hazen SJA, Kusters M. From East vs West towards international multidisciplinary collaboration: An appraisal of lateral lymph nodes in rectal cancer. Ann Gastroenterol Surg. 2021;5(6):731\u20137.","journal-title":"Ann Gastroenterol Surg"},{"issue":"1","key":"1580_CR4","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1186\/s13244-022-01303-7","volume":"13","author":"TC Sluckin","year":"2022","unstructured":"Sluckin TC, et al. Retrospective evaluation of national MRI reporting quality for lateral lymph nodes in rectal cancer patients and concordance with prospective re-evaluation following additional training. Insights Imaging. 2022;13(1):171.","journal-title":"Insights Imaging"},{"issue":"1","key":"1580_CR5","doi-asserted-by":"publisher","first-page":"17","DOI":"10.6004\/jnccn.2023.7081","volume":"22","author":"EGM van Geffen","year":"2024","unstructured":"van Geffen EGM, et al. Value of Size and Malignant Features of Lateral Lymph Nodes in Risk Stratification at Lateral Local Recurrence of Rectal Cancer: A National Cohort Study. J Natl Compr Canc Netw. 2024;22(1):17\u201325.","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"1580_CR6","doi-asserted-by":"publisher","first-page":"15071","DOI":"10.1038\/s41598-025-99029-1","volume":"15","author":"J Yoo","year":"2025","unstructured":"Yoo J, et al. Predicting lateral pelvic lymph node metastasis in rectal cancer patients using MRI radiomics: a multicenter retrospective study. Sci Rep. 2025;15(1):15071.","journal-title":"Sci Rep"},{"issue":"6","key":"1580_CR7","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/S1470-2045(12)70158-4","volume":"13","author":"S Fujita","year":"2012","unstructured":"Fujita S, et al. Postoperative morbidity and mortality after mesorectal excision with and without lateral lymph node dissection for clinical stage II or stage III lower rectal cancer (JCOG0212): results from a multicentre, randomised controlled, non-inferiority trial. Lancet Oncol. 2012;13(6):616\u201321.","journal-title":"Lancet Oncol"},{"key":"1580_CR8","unstructured":"Radiotherapy dose fractionation, in 4th Edition T.R.C.o. Radiologists, Editor. 2024 p. 7."},{"issue":"2","key":"1580_CR9","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.prro.2024.11.003","volume":"15","author":"JY Wo","year":"2025","unstructured":"Wo JY, et al. Radiation Therapy for Rectal Cancer: An ASTRO Clinical Practice Guideline Focused Update. Pract Radiat Oncol. 2025;15(2):124\u201343.","journal-title":"Pract Radiat Oncol"},{"key":"1580_CR10","doi-asserted-by":"publisher","first-page":"111409","DOI":"10.1016\/j.radonc.2026.111409","volume":"218","author":"R de Jong","year":"2026","unstructured":"de Jong R, et al. ESTRO technical guideline: intensity modulated radiotherapy and image guided radiotherapy for rectal cancer. Radiother Oncol. 2026;218:111409.","journal-title":"Radiother Oncol"},{"key":"1580_CR11","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","journal-title":"BMJ"},{"issue":"2","key":"1580_CR12","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1080\/02763869.2019.1588072","volume":"38","author":"JH Schiavo","year":"2019","unstructured":"Schiavo JH. PROSPERO: An International Register of Systematic Review Protocols. Med Ref Serv Q. 2019;38(2):171\u201380.","journal-title":"Med Ref Serv Q"},{"issue":"4","key":"1580_CR13","doi-asserted-by":"publisher","first-page":"852","DOI":"10.5195\/jmla.2023.1803","volume":"111","author":"T Gotschall","year":"2023","unstructured":"Gotschall T. Resource Review: EndNote 21 desktop version. J Med Libr Assoc. 2023;111(4):852\u20133.","journal-title":"J Med Libr Assoc"},{"key":"1580_CR14","unstructured":"Wells GA, O\u2019Connell BSD, Peterson J, Welch V, Losos M. P Tugwell. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. May 3, 2021 Copyright 2024 Ottawa Hospital Research Institute. All rights reserved.; Available from: https:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp"},{"issue":"9","key":"1580_CR15","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1046\/j.1445-2197.2003.02748.x","volume":"73","author":"K Slim","year":"2003","unstructured":"Slim K, et al. Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ J Surg. 2003;73(9):712\u20136.","journal-title":"ANZ J Surg"},{"issue":"1","key":"1580_CR16","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s13014-024-02506-6","volume":"19","author":"H Wang","year":"2024","unstructured":"Wang H, et al. Efficacy and safety of MR-guided adaptive simultaneous integrated boost radiotherapy to primary lesions and positive lymph nodes in the neoadjuvant treatment of locally advanced rectal cancer: a randomized controlled phase III trial. Radiation Oncol (London England). 2024;19(1):118.","journal-title":"Radiation Oncol (London England)"},{"key":"1580_CR17","unstructured":"Nct. Adaptive Boost Radiotherapy to Primary Lesions and Positive Nodes in the Neoadjuvant Treatment of Locally Advanced Rectal Cancer. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT06246344, 2024."},{"key":"1580_CR18","doi-asserted-by":"publisher","first-page":"627572","DOI":"10.3389\/fonc.2020.627572","volume":"10","author":"S Li","year":"2020","unstructured":"Li S, et al. Simultaneous Integrated Boost Intensity-Modulated Radiation Therapy Can Benefit the Locally Advanced Rectal Cancer Patients With Clinically Positive Lateral Pelvic Lymph Node. Front Oncol. 2020;10:627572.","journal-title":"Front Oncol"},{"key":"1580_CR19","doi-asserted-by":"crossref","unstructured":"Pang X, et al. Management of Clinically Involved Lateral Lymph Node Metastasis in Locally Advanced Rectal Cancer: A Radiation Dose Escalation Study. Frontiers in Oncology; 2021. pp. 11\u20132021.","DOI":"10.3389\/fonc.2021.674253"},{"issue":"3","key":"1580_CR20","doi-asserted-by":"publisher","first-page":"217","DOI":"10.21037\/atm-20-4040","volume":"9","author":"J-H Geng","year":"2021","unstructured":"Geng J-H, et al. Preliminary results of simultaneous integrated boost intensity-modulated radiation therapy based neoadjuvant chemoradiotherapy on locally advanced rectal cancer with clinically suspected positive lateral pelvic lymph nodes. Annals translational Med. 2021;9(3):217.","journal-title":"Annals translational Med"},{"key":"1580_CR21","doi-asserted-by":"publisher","first-page":"537","DOI":"10.2147\/CMAR.S286796","volume":"13","author":"S Li","year":"2021","unstructured":"Li S, et al. Effect of simultaneous integrated boost intensity modulated radiation therapy (Sib-imrt) and non-operative strategy on outcomes of distal rectal cancer patients with clinically positive lateral pelvic lymph node. Cancer Manage Res. 2021;13:537. EP\u2009\u2013\u2009546.","journal-title":"Cancer Manage Res"},{"issue":"5","key":"1580_CR22","doi-asserted-by":"publisher","first-page":"e372","DOI":"10.1016\/j.prro.2019.12.007","volume":"10","author":"H Chen","year":"2020","unstructured":"Chen H, et al. Effect and Safety of Radiation Therapy Boost to Extramesorectal Lymph Nodes in Rectal Cancer. Practical Radiation Oncol. 2020;10(5):e372\u2013377.","journal-title":"Practical Radiation Oncol"},{"issue":"1","key":"1580_CR23","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1097\/DCR.0000000000002936","volume":"67","author":"C Hassanzadeh","year":"2024","unstructured":"Hassanzadeh C, et al. Lateral Pelvic Nodal Management and Patterns of Failure in Patients Receiving Short-Course Radiation for Locally Advanced Rectal Cancer. Dis Colon Rectum. 2024;67(1):54\u201361.","journal-title":"Dis Colon Rectum"},{"issue":"3","key":"1580_CR24","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/j.adro.2019.03.007","volume":"4","author":"PE Hartvigson","year":"2019","unstructured":"Hartvigson PE, et al. Radiation Therapy Dose Escalation to Clinically Involved Pelvic Sidewall Lymph Nodes in Locally Advanced Rectal Cancer. Adv radiation Oncol. 2019;4(3):478\u201386.","journal-title":"Adv radiation Oncol"},{"issue":"1","key":"1580_CR25","doi-asserted-by":"publisher","first-page":"e17292","DOI":"10.1111\/codi.17292","volume":"27","author":"P Nayak","year":"2025","unstructured":"Nayak P, et al. Simultaneous integrated boost intensity-modulated radiation therapy targeting clinically involved extramesorectal lymph nodes in locally advanced rectal cancer: A retrospective study. Colorectal Dis. 2025;27(1):e17292.","journal-title":"Colorectal Dis"},{"issue":"7","key":"1580_CR26","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.3390\/cancers14071643","volume":"14","author":"E Meldolesi","year":"2022","unstructured":"Meldolesi E, et al. The Role of Simultaneous Integrated Boost in Locally Advanced Rectal Cancer Patients with Positive Lateral Pelvic Lymph Nodes. Cancers. 2022;14(7):1643.","journal-title":"Cancers"},{"issue":"7","key":"1580_CR27","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1007\/s00066-024-02354-z","volume":"201","author":"M Buttner","year":"2025","unstructured":"Buttner M, et al. Simultaneous integrated boost to lateral pelvic lymph nodes during chemoradiotherapy in high-risk rectal cancer. Strahlentherapie und Onkologie: Organ der Deutschen Rontgengesellschaft \u2026 et al]. 2025;201(7):706\u201312.","journal-title":"Strahlentherapie und Onkologie: Organ der Deutschen Rontgengesellschaft \u2026 et al]"},{"key":"1580_CR28","unstructured":"National Comprehensive Cancer, Network I. NCCN Clinical Practice Guidelines in Oncology, Colon Cancer. 2019((Version 3.2019))."},{"issue":"7","key":"1580_CR29","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/S2468-1253(17)30074-2","volume":"2","author":"F Dossa","year":"2017","unstructured":"Dossa F, et al. A watch-and-wait approach for locally advanced rectal cancer after a clinical complete response following neoadjuvant chemoradiation: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2017;2(7):501\u201313.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"2","key":"1580_CR30","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1055\/s-0036-1580632","volume":"29","author":"JH Ashburn","year":"2016","unstructured":"Ashburn JH, Kalady MF. Radiation-Induced Problems in Colorectal Surgery. Clin Colon Rectal Surg. 2016;29(2):85\u201391.","journal-title":"Clin Colon Rectal Surg"},{"key":"1580_CR31","first-page":"8197701","volume":"2022","author":"J Yang","year":"2022","unstructured":"Yang J, et al. Effects of Neoadjuvant Radiotherapy on Postoperative Complications in Rectal Cancer: A Meta-Analysis. J Oncol. 2022;2022:8197701.","journal-title":"J Oncol"}],"container-title":["Journal of Gastrointestinal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-026-01580-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12029-026-01580-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-026-01580-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T09:10:16Z","timestamp":1788772216000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12029-026-01580-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,7]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1580"],"URL":"https:\/\/doi.org\/10.1007\/s12029-026-01580-1","relation":{},"ISSN":["1941-6636"],"issn-type":[{"value":"1941-6636","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,7]]},"assertion":[{"value":"10 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declaration"}}],"article-number":"212"}}